All In Biotech

Drug Trial Radar · NCT01302119

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Last checked: Nov 19, 2026Latest source record: Apr 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 604 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

604

Actual

Start

Feb 2011

Primary completion

Dec 31, 2012

Study completion Feb 20, 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.

Conditions

  • Onychomycosis of Toenails

Interventions

  • AN2690 Topical Solution, 5%Drug

    AN2690 Topical Solution, 5%, applied once daily for 48 weeks

  • Solution VehicleDrug

    AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52Time frame: Week 52

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Phoenix, Arizona

  • Investigational Site

    Novato, California

  • Investigational Site

    Oceanside, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    San Francisco, California

  • Investigational Site

    Santa Rosa, California

  • Investigational Site

    Miami, Florida

  • Investigational Site

    Miami, Florida

  • Investigational Site

    Nampa, Idaho

  • Investigational Site

    Evansville, Indiana

  • Investigational Site

    Ann Arbor, Michigan

  • Investigational Site

    St Louis, Missouri

  • Investigational Site

    Verona, New Jersey

  • Investigational Site

    Albuquerque, New Mexico

  • Investigational Site

    High Point, North Carolina

  • Investigational Site

    Raleigh, North Carolina

  • Investigational Site

    Columbus, Ohio

  • Investigational Site

    Portland, Oregon

  • Investigational Site

    Philadelphia, Pennsylvania

  • Investigational Site

    Greer, South Carolina

  • Investigational Site

    Knoxville, Tennessee

  • Investigational Site

    Dallas, Texas

  • Investigational Site

    San Antonio, Texas

  • Investigational Site

    Salt Lake City, Utah

  • Investigational Site

    Harrisonburg, Virginia

  • Investigational Site

    Norfolk, Virginia

  • Investigational Site

    Québec, Canada

  • Investigational Site

    Barrie, Ontario, Canada

  • Investigational Site

    Markham, Ontario, Canada

  • Investigational Site

    North Bay, Ontario, Canada

  • Investigational Site

    Boucherville, Quebec, Canada

  • Investigational Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.